Menstrual migraine - pathophysiology, clinical features and treatment options
DOI:
https://doi.org/10.12775/QS.2024.20.54043Keywords
menstrual migraine, migraine, menstrual cycle, estrogens, migraine diagnosis, migraine treatmentAbstract
Introduction and purpose: Migraine is a prevalent neurological disorder, affecting significantly more women, especially during their childbearing years, due to its unique link to the menstrual cycle. Over 50% of women with migraines report a connection between their attacks and menstruation. This review aims to highlight the latest data on the pathophysiology, epidemiology, and treatment of menstrual migraines, emphasizing the need for increased attention to this condition.
Materials and Methods: A literature review was conducted using PubMed and Google Scholar, with search phrases including menstrual migraine, migraine, menstruation, migraine diagnosis, migraine treatment, and non-pharmacological migraine treatments.
Current Knowledge: Misinterpretation of diagnostic criteria results in conflicting information about the incidence, clinical characteristics, and treatment response of menstrual migraines. Furthermore, clinical studies often do not differentiate perimenstrual attacks. The role of ovarian hormones, particularly estrogen, in the pathogenesis of menstrual migraines complicates treatment efforts.
Summary: Due to the common and debilitating nature of the menstrual migraine, more detailed research is essential to expand our understanding of its pathophysiology and to develop more effective treatments. Understanding the mechanisms behind menstrual migraines may lead to new treatment options targeting this specific condition.
References
Aguilar-Shea AL, Membrilla MD JA, Diaz-de-Teran J. Migraine review for general practice. Atención Primaria. 2022;54(2):102208. doi:https://doi.org/10.1016/j.aprim.2021.102208.
Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. The Journal of Headache and Pain. 2020;21(1). doi:https://doi.org/10.1186/s10194-020-01208-0.
Lipton RB, Munjal S, Alam A, et al. Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender Differences. Headache: The Journal of Head and Face Pain. 2018;58(9):1408-1426. doi:https://doi.org/10.1111/head.13407.
Nappi RE, Tiranini L, Sacco S, De Matteis E, De Icco R, Tassorelli C. Role of Estrogens in Menstrual Migraine. Cells. 2022;11(8):1355. doi:https://doi.org/10.3390/cells11081355.
Allais G, Chiarle G, Sinigaglia S, Benedetto C. Menstrual migraine: a Review of Current and Developing Pharmacotherapies for Women. Expert Opinion on Pharmacotherapy. 2017;19(2):123-136. doi:https://doi.org/10.1080/14656566.2017.1414182.
Cupini LM, Corbelli I, Sarchelli P. Menstrual migraine: what is it and does it matter? Journal of Neurology. 2020;268(7):2355-2363. doi:https://doi.org/10.1007/s00415-020-09726-2.
Classification and Diagnostic Criteria for Headache Disorders, Cranial Neuralgias and Facial Pain (1988) Headache classification committee of the International Headache Society. Cephalalgia 8(Suppl 7):1-96.
Headache Classification Subcommittee of the International Headache Society (2004) The international classification of headache disorders: 2nd edition. Cephalalgia 24(Suppl 1):9-160.
Maasumi K, Tepper SJ, Kriegler JS. Menstrual Migraine and Treatment Options: a Review. Headache: The Journal of Head and Face Pain. 2016;57(2):194-208. doi:https://doi.org/10.1111/head.12978.
Headache Classification Committee of the International Headache Society (IHS) (2013) The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 33:629-808.
Vetvik KG, MacGregor EA, Lundqvist C, Russell MB. Prevalence of menstrual migraine: A population-based study. Cephalalgia. 2013;34(4):280-288. doi:https://doi.org/10.1177/0333102413507637.
Tepper SJ, Zatochill M, Szeto M, Sheftell F, Tepper DE, Bigal M. Development of A Simple Menstrual Migraine Screening Tool for Obstetric and Gynecology Clinics: the Menstrual Migraine Assessment Tool. Headache: The Journal of Head and Face Pain. 2008;48(10):1419-1425. doi:https://doi.org/10.1111/j.1526-4610.2008.01304.x.
Vetvik KG, MacGregor EA. Menstrual migraine: a distinct disorder needing greater recognition. Lancet Neurol. 2021 Apr;20(4):304-315. doi: 10.1016/S1474-4422(20)30482-8. epub 2021 Feb 15. PMID: 33600767.
Roeder HJ, Leira EC. Effects of the Menstrual Cycle on Neurological Disorders. Current Neurology and Neuroscience Reports. 2021;21(7):34. doi:https://doi.org/10.1007/s11910-021-01115-0.
Krause DN, Warfvinge K, Haanes KA, Edvinsson L. Hormonal influences in migraine - interactions of oestrogen, oxytocin and CGRP. Nature Reviews Neurology. 2021;17(10):621-633. doi:https://doi.org/10.1038/s41582-021-00544-2.
MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology. 2006;67(12):2154-2158. doi:https://doi.org/10.1212/01.wnl.0000233888.18228.19.
Lichten EM, Lichten JB, Whitty A, Pieper D. The Confirmation of a Biochemical Marker for Women's Hormonal Migraine: the Depo-Estradiol Challenge Test. Headache: The Journal of Head and Face Pain. 1996;36(6):367-371. doi:https://doi.org/10.1046/j.1526-4610.1996.3606367.x.
Machado RB, Pereira AP, Coelho GP, Neri L, Martins L, Luminoso D. Epidemiological and clinical aspects of migraine in users of combined oral contraceptives. Contraception. 2010;81(3):202-208. doi:https://doi.org/10.1016/j.contraception.2009.09.006.
Somerville BW. The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology. 1972;22(4):355-355. doi:https://doi.org/10.1212/wnl.22.4.355.
Somerville BW. The role of progesterone in menstrual migraine. Neurology. 1971;21(8):853-853. doi:https://doi.org/10.1212/wnl.21.8.853.
Petrovski BÉ, Vetvik KG, Lundqvist C, Eberhard-Gran M. Characteristics of menstrual versus non-menstrual migraine during pregnancy: a longitudinal population-based study. The Journal of Headache and Pain. 2018;19(1). doi:https://doi.org/10.1186/s10194-018-0853-3.
Burch R. Epidemiology and Treatment of Menstrual Migraine and Migraine During Pregnancy and Lactation: A Narrative Review. Headache: The Journal of Head and Face Pain. 2019;60(1):200-216. doi:https://doi.org/10.1111/head.13665.
Yamanaka G, Suzuki S, Morishita N, et al. Role of Neuroinflammation and Blood-Brain Barrier Permutability on Migraine. International Journal of Molecular Sciences. 2021;22(16):8929. doi:https://doi.org/10.3390/ijms22168929.
Iyengar S, Ossipov MH, Johnson KW. The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. PAIN. 2017;158(4):543-559. doi:https://doi.org/10.1097/j.pain.000000000000083.
Wyon Y, Frisk J, Lundeberg T, Elvar Theodorsson, Hammar M. Postmenopausal women with vasomotor symptoms have increased urinary excretion of calcitonin gene-related peptide. Maturitas. 1998;30(3):289-294. doi:https://doi.org/10.1016/s0378-5122(98)00047-4.
Ibrahimi K, Danser A, Villalón C, van den Meiracker A, MaassenVanDenBrink A. Influence of varying estrogen levels on trigeminal CGRP release in healthy women. The Journal of Headache and Pain. 2013;14(S1). doi:https://doi.org/10.1186/1129-2377-14-s1-p123.
Ayhan Cetinkaya, Erkan Kilinc, Cagri Camsari, Muhammed Nur Ogun. Effects of estrogen and progesterone on the neurogenic inflammatory neuropeptides: implications for gender differences in migraine. Experimental Brain Research. 2020;238(11):2625-2639. doi:https://doi.org/10.1007/s00221-020-05923-7.
Smith YR. Pronociceptive and Antinociceptive Effects of Estradiol through Endogenous Opioid Neurotransmission in Women. Journal of Neuroscience. 2006;26(21):5777-5785. doi:https://doi.org/10.1523/jneurosci.5223-05.2006.
Fuentes N, Silveyra P. Estrogen receptor signaling mechanisms. Advances in Protein Chemistry and Structural Biology. 2019;116:135-170. doi:https://doi.org/10.1016/bs.apcsb.2019.01.001.
Borsook D, Erpelding N, Lebel A, et al. Sex and the migraine brain. Neurobiology of Disease. 2014;68:200-214. doi:https://doi.org/10.1016/j.nbd.2014.03.008.
Antonova M, Wienecke T, Olesen J, Ashina M. Prostaglandin E2 induces immediate migraine-like attack in migraine patients without aura. Cephalalgia. 2012;32(11):822-833. doi:https://doi.org/10.1177/0333102412451360.
Mannix LK. Menstrual-Related Pain Conditions: Dysmenorrhea and Migraine. Journal of Women's Health. 2008;17(5):879-891. doi:https://doi.org/10.1089/jwh.2007.0440.
Sutherland HG, Champion M, Plays A, et al. Investigation of polymorphisms in genes involved in estrogen metabolism in menstrual migraine. Gene. 2017;607:36-40. doi:https://doi.org/10.1016/j.gene.2017.01.008.
Pollock CE, Sutherland HG, Maher BH, et al. The NRP1 migraine risk variant shows evidence of association with menstrual migraine. The Journal of Headache and Pain. 2018;19(1). doi:https://doi.org/10.1186/s10194-018-0857-z.
Rodriguez-Acevedo AJ, Smith RA, Roy B, et al. Genetic association and gene expression studies suggest that genetic variants in the SYNE1 and TNF genes are related to menstrual migraine. The Journal of Headache and Pain. 2014;15(1). doi:https://doi.org/10.1186/1129-2377-15-62.
Khan J, Asoom LIA, Sunni AA, et al. Genetics, pathophysiology, diagnosis, treatment, management, and prevention of migraine. Biomed Pharmacother. 2021 Jul;139:111557. doi: 10.1016/j.biopha.2021.111557.
Lucas C. Migraine with aura. Revue Neurologique. 2021;177(7):779-784. doi:https://doi.org/10.1016/j.neurol.2021.07.010.
Vetvik KG, Benth JŠ, MacGregor EA, Lundqvist C, Russell MB. Menstrual versus non-menstrual attacks of migraine without aura in women with and without menstrual migraine. Cephalalalgia. 2015;35(14):1261-1268. doi:https://doi.org/10.1177/0333102415575723.
Jensen TS, Finnerup NB. Allodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms. The Lancet Neurology. 2014;13(9):924-935. doi:https://doi.org/10.1016/S1474-4422(14)70102-4.
Güven B, Güven H, Çomoğlu S. Clinical characteristics of menstrually related and non-menstrual migraine. Acta Neurologica Belgica. 2017;117(3):671-676. doi:https://doi.org/10.1007/s13760-017-0802-y.
Barra M, Dahl FA, MacGregor EA, Vetvik KG. Identifying menstrual migraine- improving the diagnostic criteria using a statistical method. The Journal of Headache and Pain. 2019;20(1). doi:https://doi.org/10.1186/s10194-019-1035-7.
Marcus DA, Bernstein CD, Sullivan EA, Rudy TE. A Prospective Comparison Between ICHD-II and Probability Menstrual Migraine Diagnostic Criteria. Headache: The Journal of Head and Face Pain. 2010;50(4):539-550. doi:https://doi.org/10.1111/j.1526-4610.2010.01627.x.
Nappi G, Jensen R, Nappi R, Sances G, Torelli P, Olesen J. Diaries and Calendars for Migraine. A Review. Cephalalgia. 2006;26(8):905-916. doi:https://doi.org/10.1111/j.1468-2982.2006.01155.x.
Allais G., Tullo V, Benedetto C, Zava D, Stefano Omboni, Bussone G. Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, multicenter, Italian, comparative study versus zolmitriptan. Neurological Sciences. 2011;32(S1):99-104. doi:https://doi.org/10.1007/s10072-011-0547-y.
Mannix LK, Martin VT, Cady R, et al. Combination Treatment for Menstrual Migraine and Dysmenorrhea Using Sumatriptan-Naproxen. Obstetrics & Gynecology. 2009;114(1):106-113. doi:https://doi.org/10.1097/aog.0b013e3181a98e4d.
Hu Y, Guan X, Fan L, Jin L. Triptans in prevention of menstrual migraine: a systematic review with meta-analysis. The Journal of Headache and Pain. 2013;14(1). doi:https://doi.org/10.1186/1129-2377-14-7.
Allais G, del Rio MS, Diener HC, et al. Perimenstrual migraines and their response to preventive therapy with topiramate. Cephalalgia. 2010;31(2):152-160. doi:https://doi.org/10.1177/0333102410378049.
Jiang Y, Huang ZL. Recent advances in targeting calcitonin gene-related peptide for the treatment of menstrual migraine. Medicine. 2022;101(24):e29361. doi:https://doi.org/10.1097/md.0000000000029361.
Coffee AL, Sulak PJ, Hill AJ, Hansen DJ, Kuehl TJ, Clark JW. Extended Cycle Combined Oral Contraceptives and Prophylactic Frovatriptan During the Hormone-Free Interval in Women with Menstrual-Related Migraines. Journal of Women's Health. 2014;23(4):310-317. doi:https://doi.org/10.1089/jwh.2013.4485.
De Leo V, Scolaro V, Musacchio MC, Di Sabatino A, Morgante G, Cianci A. Combined oral contraceptives in women with menstrual migraine without aura. Fertility and Sterility. 2011;96(4):917-920. doi:https://doi.org/10.1016/j.fertnstert.2011.07.1089.
Tassorelli C, Greco R, Allena M, Terreno E, Nappi RE. Transdermal Hormonal Therapy in Perimenstrual Migraine: Why, When and How? Current Pain and Headache Reports. 2012;16(5):467-473. doi:https://doi.org/10.1007/s11916-012-0293-8.
Morotti M, Remorgida V, Venturini PL, Ferrero S. Progestin-only contraception compared with extended combined oral contraceptive in women with migraine without aura: a retrospective pilot study. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2014;183:178-182. doi:https://doi.org/10.1016/j.ejogrb.2014.10.029.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Dominika Szczotka, Dominika Opala, Dobromiła Osuch, Izabela Staszczyk, Aleksandra Drabik, Antonina Szemplińska, Klaudia Błachnio, Agnieszka Anderska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 97
Number of citations: 0
